We are live on ! Find out more

ELOX

Eloxx Pharmaceuticals

ELOX

Market cap $60.6M

17.63 USD

-0.62

3.4%

At close Updated Sep 16, 4:00 PM EDT

1 day

-3.4%

5 days

6.85%

1 month

-4.55%

3 months

38.27%

6 months

60.13%

Year to date

60.13%

1 year

60.13%

5 years

60.13%

10 years

60.13%

About: Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Employees: 7

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™